Leucht, S, Arbter, D, Engel, RR, Kissling, W, Davis, JM. How effective are second-generation antipsychotic
drugs? A meta-analysis of placebo-controlled trials.
2009; 14: 429–47.
Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical
2006; 31: 2318–25.
Lepping, P, Sambhi, RS, Whittington, R, Lane, S, Poole, R. Clinical relevance of findings in trials of
antipsychotics: systematic review. Br J
2011; 198: 341–5.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation
antipsychotic drugs for schizophrenia: a meta-analysis.
Artaloytia, JF, Arango, C, Lahti, A, Sanz, J, Pascual, A, Cubero, P, et al. Negative signs and symptoms secondary to
antipsychotics: a double-blind, randomized trial of a single dose of
placebo, haloperidol, and risperidone in healthy
volunteers. Am J Psychiatry
2006; 163: 488–93.
Moncrieff, J, Leo, J. A systematic review of the effects of antipsychotic
drugs on brain volume. Psychol Med
2010; 40: 1409–22.
Ray, WA, Chung, CP, Murray, KT, Hall, K, Stein, CM. Atypical antipsychotic drugs and the risk of sudden
cardiac death. N Engl J Med
2009; 360: 225–35.
Weinmann, S, Read, J, Aderhold, V. Influence of antipsychotics on mortality in
schizophrenia: systematic review. Schizophr
Foley, DL, Morley, KI. Systematic review of early cardiometabolic outcomes
of the first treated episode of psychosis. Arch
2011; 68: 609–16.
Álvarez-Jiménez, M, Hetrick, SE, González-Blanch, C, Gleeson, JF, McGorry, PD. Non-pharmacological management of
antipsychotic-induced weight gain: systematic review and meta-analysis of
randomised controlled trials. Br J
2008; 193: 101–7.
Marques, TR, Arenovich, T, Agid, O, Sajeev, G, Muthen, B, Chen, L, et al. The different trajectories of antipsychotic
response: antipsychotics versus placebo. Psychol
2011; 41: 1481–8.
Perkins, D, Lieberman, J, Gu, H, Tohen, M, McEvoy, J, Green, A, et al. Predictors of antipsychotic treatment
response in patients with first-episode schizophrenia, schizoaffective
and schizophreniform disorders. Br J
Harrow, M, Jobe, TH, Faull, RN. Do all schizophrenia patients need antipsychotic
treatment continuously throughout their lifetime? A 20-year longitudinal
study. In Psychol Med
Morrison, AP, Hutton, P, Wardle, M, Spencer, H, Barratt, S, Brabban, A, et al. Cognitive therapy for people with a
schizophrenia spectrum diagnosis not taking antipsychotic medication: an
exploratory trial. Psychol Med
2012; 42: 1049–56.
Day, JC, Bentall, RP, Roberts, C, Randall, F, Rogers, A, Cattell, D, et al. Attitudes toward antipsychotic medication:
the impact of clinical variables and relationships with health
professionals. Arch Gen Psychiatry
2005; 62: 717–24.